Nodular Sclerosing Hodgkin Lymphoma

Namanin sclerosing Hodgkin lymphoma, ciwon daji na kwayoyin lymph, shine irin cutar Hodgkin. Yawancin lymphoma na Hodgkin ya fi kowa a cikin kasashe masu tasowa, yana da kashi 60 zuwa 80 cikin dari na duk wadanda ke fama da wannan cuta.

Nodular sclerosing Hodgkin lymphoma shafi mafi yawa matasa da matasa. Har ila yau, ya fi yawa a cikin 'yan mata fiye da yara.

Sunan 'nodular sclerosing' an samo daga bayyanar kwayar ƙumbadar ƙwayar lymph a karkashin microscope a cikin irin wannan lymphoma Hodgkin.

Babban alamar bayyanar cututtuka na nodular Hodgkin lymphoma sun kara girma a cikin wuyan wuyansa, ko kuma cikin kirji . An gane ganewar asali na lymphoma tare da kwayar cutar kwayar lymph.

Mafi yawancin mutane ana bincikar su a farkon matakan kuma za'a iya warkar da su tare da magani wanda ya hada da chemotherapy da radiation far.

Daya daga Hodgkin Lymphomas daban-daban

Sunan dukkanin lymphoma iri iri da subtypes suna da rikicewa har ma likitoci waɗanda basu kula da su akai-akai. Hodgkin cuta da Hodgkin lymphoma daidai daidai da wancan, duk da haka, akwai da yawa daban-daban lymphoma, wanda Hodgkin ne kawai daya. Kuma akwai daban-daban na lymphoma Hodgkin, ma. Don haka, a nan ne raguwa na lymphoma Hodgkin na nodular sclerosing dangane da inda ya dace a cikin hoto mafi girma na lymphomas:

Hali na biyu na lymphoma su ne Hodgkin da lymphoma non-Hodgkin .

Hodgkin lymphoma za a iya kara kara karya zuwa cikin 2 kungiyoyi:

"Maɗarin lymphocyte da yawa" kuma "nodular sclerosing" ba iri daya bane - suna komawa zuwa nau'o'i daban-daban na lymphoma Hodgkin.

Nodular Sclerosing Hodgkin lymphoma - lymphoma a halin yanzu an bayyana - shi ne subtype na Classic Hodgkin lymphoma. Lymphoma na Classic Hodgkin yana da siffa hudu masu zuwa:

Ayyuka: Nodular Sclerosing Classic Hodgkin Lymphoma

Nodular sclerosis Hodgkin lymphoma (NSHL) shi ne mafi yawan al'ada-pathology na tushen subtype tsakanin matasa da matasa a cikin kasashen masana'antu. NSHL ma yana da gagarumin rinjaye, tare da haɗakar ƙwayar ƙwayar cuta 100 a ninki biyu.

Kwanan nan, an gudanar da babban binciken da aka yi game da haɗin radiation ultraviolet daga rana da kuma wasu subtypes na lymphoma na Hodgkin. A cikin binciken da Emily Bowen da abokan aiki suka yi, Hodgkin lymphoma ya kasance mafi ƙasƙanci a cikin kungiyoyi masu yawa wanda ya fi dacewa da hasken rana. Kodayake wannan binciken ya kasance wani bala'i, kawai, wannan yanayin ya bayyana ya zama mai gaskiya a cikin mutane tare da nodular sclerosis subtype.

Sauran nazarin na baya-bayan nan suna binciken wani farfadowa, ba da izini ba, kuma yadda za'a iya hulɗa tare da matakai daban-daban da aka sani da za a yi a wasu siffofin HL na al'ada.

Wani binciken da Bitrus Hollander da abokan aikinsa suka yi sunyi bayanin cewa ba da izini ba ne a kan hanyar da aka tsara ta hanyar yin amfani da na'urar ta hanyar mutuwa (PD) -1 shine sabon tsarin kulawa a cikin ƙwayar lymphoma na Hodgkin na gargajiya.

Wannan rukuni ta gano cewa wasu halaye na kwayoyin da aka gano a duk tarin tumo, kuma ba daga kwayoyin tumo da kansu ba, an danganta su zuwa hangen nesa. Binciken ya gano cewa sakamakon da aka samu a HL sun kasance mafi muni lokacin da waɗannan kwayoyin jini masu launin jini, ko kwayoyin halitta, sun kasance a cikin manyan hanyoyi na PD-1 da PD-L1. Sun bayar da shawarar cewa waɗannan rukuni na marasa lafiya za su iya amfana daga mafi yawan cututtukan chemotherapy da kuma, watakila, daga masu hana PD-1 a matsayin magani na gaba.

> Sources:

> Cozen W, Li D, Mafi T, et al. Hanyoyin maganin maganin ƙwayoyin ƙwayoyin ƙwayoyin cuta na kwayoyin Hodgkin lymphoma suna nuna haɗarin hadarin a 6p21.32. Jinin jini. 2012; 119 (2): 469-475.

> Hollander P, Kamper P, Ekstrom K, et al. Matsayi mai girma na PD-1 + da PD-L1 + leukocytes a cikin ƙwayoyin lymphoma na Hodgkin na yau da kullum suna da alaƙa da sakamako mai zurfi. Bayanin Blood. 2017; 1 (18): 1427-1439.

> Kunna EM, Pfeiffer RM, Linet MS, et al. Hulɗar dangantaka tsakanin radiation ultraviolet radiation da Hodgkin lymphoma subtypes a Amurka. Jaridar British Journal of Cancer. 2016; 114 (7): 826-831.